Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch cautioned against too much pessimism, writing “this continued uncertainty is likely ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

On Jan. 30, Leerink Partners analyst Daina Graybosch maintained a “Buy” rating on MRK with a price target of $118, implying a potential upside of 18.2% from current levels. The mean price ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, ...

Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. Recognized as one of ...

Across the recent three months, 12 analysts have shared their insights on Merck & Co MRK, expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a ...